Zyprexa Class Action Lawsuit - CASE SETTLED

Girard Gibbs represented several patients in lawsuits involving the drug Zyprexa, also known as Olanzapine, an atypical antipsychotic medication manufactured by Eli Lilly and Company.

Zyprexa was approved and released on the market in 1996 and was primarily prescribed for the treatment of schizophrenia and bipolar disorder as well as dementia and anxiety. Numerous lawsuits were filed throughout the country alleging that patients who use Zyprexa have an increased likelihood of developing a number of serious side effects, which the lawsuits allege were undisclosed or inadequately disclosed.

On June 10, 2005, Eli Lilly announced an agreement to settle thousands of lawsuits and claims brought on behalf of persons who claimed to have been harmed by the side effects of taking Zyprexa that were not adequately disclosed ("Zyprexa side effects lawsuit"). In total, Lilly paid more than $1.2 billion to settle these lawsuits with 28,500 people.

Why Girard Gibbs LLP?

Girard Gibbs is a national litigation firm specializing in securities litigation, consumer class actions and complex business litigation. Girard Gibbs' managing partner Daniel Girard was voted one of Northern California's Super Lawyers in 2007, 2008, and 2009 by Law & Politics, recognizing him as one of the top 5-percent of attorneys practicing in Northern California.